This is a Phase 2 3-arm, open label pilot study of the safety and efficacy of Q8003 in patients who have undergone primary unilateral total knee arthroplasty or total hip arthroplasty.
This Phase 2 study is a 3 arm, open-label pilot study to evaluate: * the analgesic efficacy of a flexible ascending regimen of Q8003 compared to a low dose regimen of Q8003 (3 mg/2 mg and potentially up to 6 mg/ 4mg) and to 1-2 Percocet® 5 mg/325 mg tablets. Study drug will be administered every 4-6 hours over a 48-hour Treatment Period to inpatients with moderate to severe postoperative pain who have undergone primary unilateral total knee arthroplasty or total hip arthroplasty. * for the flexible ascending regimen of Q8003 treatment group, to evaluate the adequacy of the algorithm for conversion of IV PCA morphine to oral morphine equivalent doses of Q8003. * the safety of the flexible ascending regimen of Q8003 administered over a 48-hour Treatment Period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
44
IR Capsules, ascending flexible dose, every 4 to 6 hours
One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
One or two 5mg/325 mg tablets every 4 to 6 hours
West Alabama Research, Inc.
Birmingham, Alabama, United States
Arizona Research Center
Phoenix, Arizona, United States
William Beaumont Hospital
Royal Oak, Michigan, United States
Research Concepts, Ltd.
Houston, Texas, United States
Difference in pain intensity scores from baseline
Time frame: 48 hours
Safety: adverse events
Time frame: Throughout the 48 hour period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.